Inspire Veterinary Partners, INC

Erinn Thomas-Mackey has resigned from the Board of Directors of Inspire Veterinary Partners Inc., effective February 26, 2026.

Inspire Veterinary Partners, Inc. announced its Class A common stock was delisted from Nasdaq and began trading on the OTCQB Venture Market under the symbol IVPR.

Inspire Veterinary Partners, Inc. converted $25,000 of debt into 2.5 million shares of Class A common stock with Target Capital 1 LLC.

Inspire Veterinary Partners, Inc. has increased its authorized Class A common stock from 100 million to 700 million shares, effective January 9, 2026.

Inspire Veterinary Partners, Inc. has entered into a securities purchase agreement for a $975,000 secured convertible promissory note and issued 2 million commitment shares, with proceeds for working capital and acquisitions.

Inspire Veterinary Partners, Inc. converted $150,000 of outstanding debt into 3,000,000 shares of common stock with Target Capital 1 LLC.

Inspire Veterinary Partners reported a reduced net loss for Q3 2025, despite a slight decrease in total revenue, as it continues its acquisition strategy and manages high-interest debt.

Inspire Veterinary Partners reports a reduced net loss and improved clinic EBITDA for Q2 2025, but faces substantial doubt about its going concern status and Nasdaq listing compliance.

Inspire Veterinary Partners' Q1 2025 revenue decreased by 25% year-over-year, primarily due to the divestiture of Kauai Veterinary Clinic and reduced DVM capacity.

Inspire Veterinary Partners saw a slight increase in service revenue but experienced a net loss of $3.49 million for the third quarter of 2024, impacted by higher operating expenses and interest costs.

Inspire Veterinary Partners' Q2 2024 results show a significant increase in net loss compared to the same period last year, driven by higher operating expenses and debt extinguishment losses.

Inspire Veterinary Partners reports a significant increase in net losses for the second quarter of 2024, despite a rise in service revenue and ongoing expansion through acquisitions.

Inspire Veterinary Partners' 2024 annual report reveals a $14.3 million net loss and raises concerns about the company's ability to continue as a going concern.

Inspire Veterinary Partners, Inc. released its 10-K annual report, outlining its financial performance, strategic initiatives, and risks for the fiscal year ended December 31, 2023.

INSPIRE VETERINARY PARTNERS Director Erinn Thomas-Mackey reported the acquisition of 1,447 stock options, adjusted for a recent reverse stock split.

Director Timothy Watters acquires 1,447 stock options in Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners Director Anne Murphy acquired 1,447 Class A Common Stock options, adjusted for a 25-to-1 reverse stock split, though the filing was submitted late due to administrative error.

Inspire Veterinary Partners Director Lawrence Alexander acquired 1,447 stock options, adjusted for a recent 25-to-1 reverse stock split, with the filing noted as late due to administrative error.

Inspire Veterinary Partners director Charles Stith Keiser acquired 953 stock options at an exercise price of $17, adjusted for a recent reverse stock split.

Inspire Veterinary Partners CFO Richard Frank acquired 58,480 stock options at an exercise price of $1.71, exercisable from April 1, 2025.

Inspire Veterinary Partners, Inc. stockholders approved an amendment to increase authorized Class A Common Stock to 700 million shares.

Inspire Veterinary Partners, Inc. announces an increase in its authorized Class A Common Stock to 700 million shares, approved by majority stockholders via written consent.

Inspire Veterinary Partners, Inc. has filed definitive additional materials related to a proxy statement with the SEC.

Inspire Veterinary Partners, Inc. disclosed a 'going concern' warning from its former auditor and material weaknesses in internal controls, alongside routine annual meeting proposals.

Majority stockholders approved the issuance of common stock related to a $60 million private placement to accredited investors.

Inspire Veterinary Partners announces stockholder approval for a private placement involving the issuance of common stock and warrants.

Inspire Veterinary Partners, Inc. filed an S-1/A registration statement detailing its delisting from Nasdaq, ongoing financial losses, and plans to raise up to $1.625 million through secured convertible promissory notes.

Inspire Veterinary Partners, a U.S. veterinary hospital operator, is awaiting a Nasdaq delisting decision while pursuing highly dilutive convertible note financing and reporting continued net losses despite some operational improvements.

Inspire Veterinary Partners reports reduced net losses and improved cash flow from operations, but faces imminent Nasdaq delisting and ongoing 'going concern' doubts.

Inspire Veterinary Partners, Inc. filed an S-1 registration statement for the potential resale of up to 46.4 million shares of Class A common stock by selling stockholders, including shares from Series B preferred stock conversion and warrant exercises.

Inspire Veterinary Partners files S-1 to register up to 35 million shares for resale by Seven Knots, securing a crucial $50 million equity financing commitment amidst ongoing losses and dilution concerns.

A U.S. veterinary hospital operator is seeking to raise up to $5 million through a unit offering to fund working capital and acquisitions, while grappling with significant net losses and a Nasdaq listing deficiency.

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Inspire Veterinary Partners, Inc. Class A Common Stock.

Armistice Capital, LLC and Steven Boyd report a 9.99% beneficial ownership stake in Inspire Veterinary Partners, Inc. Class A Common Stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, revealing a passive beneficial ownership of 9.99% of Inspire Veterinary Partners, Inc.'s Class A Common Stock.